Back to top
more

Enliven Therapeutics, Inc. (ELVN)

(Real Time Quote from BATS)

$18.00 USD

18.00
152,113

-0.84 (-4.46%)

Updated Aug 7, 2025 02:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 75.7% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Enliven Therapeutics, Inc. (ELVN) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

Enliven Therapeutics, Inc. (ELVN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Equity Research

Here's Why Momentum in Enliven Therapeutics, Inc. (ELVN) Should Keep going

by Zacks Equity Research

Enliven Therapeutics, Inc. (ELVN) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks Equity Research

Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 58.8% in Enliven Therapeutics, Inc. (ELVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Wall Street Analysts Think Enliven Therapeutics, Inc. (ELVN) Could Surge 43.04%: Read This Before Placing a Bet

by Zacks Equity Research

The consensus price target hints at a 43% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Shrabana Mukherjee headshot

3 Stocks in the Limelight on New Analyst Coverage

by Shrabana Mukherjee

Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Disc Medicine (IRON), Westamerica (WABC) and Enliven (ELVN).